Back

HNF1A is a novel BRD4 target and critical for BET-inhibitor response in pancreatic ductal adenocarcinoma

Humphrey, K. S.; Crawford, K. J.; Muppavarapu, B.; Mayberry, M. M.; Morris, W.; Torres, E.; Long, M. D.; Wang, J.; Knudsen, E. S.; Witkiewicz, A. K.; Abel, E. V.

2025-10-02 cancer biology
10.1101/2025.10.01.679805 bioRxiv
Show abstract

Pancreatic ductal adenocarcinoma (PDAC) is an exceedingly lethal cancer that lacks actionable molecular drivers, limiting precision treatment options. We previously identified the transcription factor, HNF1A, as a novel driver of tumorigenesis and pancreatic cancer stem cell (PCSC) properties in PDAC; however, HNF1A-targeting modalities do not currently exist. Here we show that HNF1A is a direct target of the epigenetic reader protein, BRD4, and its expression is exquisitely sensitive to BET-inhibitors (BETi), which inhibit PDAC cell proliferation and block PCSC-properties in a panel of HNF1A-expressing cell lines and patient-derived xenograft cells. Remarkably, we report that the antineoplastic activity of BETi/BRD4 knockdown can be overcome by restoration of HNF1A expression, but not by re-expression of canonical BETi target MYC. RNA-sequencing analyses revealed that a subset of BETi-responsive transcripts is dependent on HNF1A expression, including receptor tyrosine kinases (RTKs), regulators and ligands. Consistent with these data, we found that HNF1A restoration rescued EGFR/ERBB3-signaling and the protective effects of HNF1A restoration could be overcome with EGFR-inhibitors. Furthermore, we found that expressions of HNF1A, BRD4, and ERBB3 were strongly correlated across PDAC patient samples using multispectral immunofluorescence, supporting a connection between these players in PDAC biology, and high expression of ERBB3 associated with better survival, supporting the clinical importance of this network in patient outcomes. These findings demonstrate that BETi can be used to ablate HNF1A expression and that the inhibition of HNF1A is critical for BETi activity, while supporting HNF1A as novel therapeutic target in PDAC. SignificanceThis study demonstrates that the oncogenic transcription factor HNF1A is a direct target of BRD4, and that the ablation of HNF1A by BET-inhibitors is central to their antineoplastic activity in PDAC.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Cancer Discovery
61 papers in training set
Top 0.1%
21.6%
2
Nature Communications
4913 papers in training set
Top 31%
6.1%
3
Cancer Cell
38 papers in training set
Top 0.2%
6.1%
4
Gastroenterology
40 papers in training set
Top 0.4%
6.1%
5
Nature Genetics
240 papers in training set
Top 1%
6.1%
6
Cell Reports
1338 papers in training set
Top 12%
4.1%
50% of probability mass above
7
Developmental Cell
168 papers in training set
Top 5%
3.8%
8
Nature Cancer
35 papers in training set
Top 0.4%
2.8%
9
Gut
36 papers in training set
Top 0.3%
2.5%
10
Journal of Experimental Medicine
106 papers in training set
Top 1%
2.5%
11
Immunity
58 papers in training set
Top 2%
2.0%
12
Cancer Research
116 papers in training set
Top 2%
2.0%
13
Cell Genomics
162 papers in training set
Top 3%
1.8%
14
eLife
5422 papers in training set
Top 39%
1.8%
15
Cell
370 papers in training set
Top 11%
1.7%
16
Journal of Clinical Investigation
164 papers in training set
Top 3%
1.6%
17
Molecular Cell
308 papers in training set
Top 7%
1.6%
18
Cell Stem Cell
57 papers in training set
Top 1%
1.6%
19
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 35%
1.4%
20
Nature Cell Biology
99 papers in training set
Top 3%
1.3%
21
Genes & Development
90 papers in training set
Top 0.7%
1.3%
22
Science Advances
1098 papers in training set
Top 24%
1.2%
23
Science
429 papers in training set
Top 17%
1.2%
24
Science Translational Medicine
111 papers in training set
Top 4%
1.2%
25
Oncogene
76 papers in training set
Top 1%
1.2%
26
The EMBO Journal
267 papers in training set
Top 4%
0.9%
27
Nature
575 papers in training set
Top 14%
0.9%
28
Cell Metabolism
49 papers in training set
Top 2%
0.9%
29
Genome Medicine
154 papers in training set
Top 7%
0.9%
30
Molecular Cancer
14 papers in training set
Top 0.9%
0.8%